Maynard Um
-
-
-
-
-
-
-
Ascendis launches YUVIWEL for achondroplasia in US market
-
-
-
-
-
-
-
Ascendis Pharma (ASND) PT Raised to $295 at Leerink Partners
-
-
-
-
-
-
-
RBC Capital: 'KOL Sees Ascendis Pharma's (ASND) Commercial Momentum Continuing Steadily From Here'
-
-
-
-
-
-
-
Ascendis (ASND) Reiterated at Buy by Stifel on Yprvipath Beat
-
-
-
-
-
-
-
Ascendis Pharma's (ASND) PDUFA Extension a Minor Issue - Cantor Fitzgerald
-
-
-
-
-
-
-
Goldman Sachs on Ascendis Pharma (ASND): 'in transition to profitability'
-
-
-
-
-
-
-
Buy weakness in this pharma stock: Wells Fargo
-
401,628 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

